• Je něco špatně v tomto záznamu ?

TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation

E. Iscan, U. Ekin, G. Yildiz, O. Oz, U. Keles, A. Suner, G. Cakan-Akdogan, G. Ozhan, M. Nekulova, B. Vojtesek, H. Uzuner, G. Karakülah, H. Alotaibi, M. Ozturk

. 2021 ; 13 (4) : . [pub] 20210213

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010471

Grantová podpora
113S389 TUBITAK
- Turkish Academy of Sciences
- Izmir Biomedicine and Genome Center
MMCI, 00209805 MH CZ - DRO
19-06530S Grant Agency of the Czech Republic
No.CZ.02.1.01/0.0/0.0/16_019/0000868 European Regional Development Fund-Project ENOCH
- EMBO Installation Grant
- TUBITAK

Hepatocyte dedifferentiation is a major source of hepatocellular carcinoma (HCC), but its mechanisms are unknown. We explored the p73 expression in HCC tumors and studied the effects of transcriptionally active p73β (TAp73β) in HCC cells. Expression profiles of p73 and patient clinical data were collected from the Genomic Data Commons (GDC) data portal and the TSVdb database, respectively. Global gene expression profiles were determined by pan-genomic 54K microarrays. The Gene Set Enrichment Analysis method was used to identify TAp73β-regulated gene sets. The effects of TAp73 isoforms were analyzed in monolayer cell culture, 3D-cell culture and xenograft models in zebrafish using western blot, flow cytometry, fluorescence imaging, real-time polymerase chain reaction (RT-PCR), immunohistochemistry and morphological examination. TAp73 isoforms were significantly upregulated in HCC, and high p73 expression correlated with poor patient survival. The induced expression of TAp73β caused landscape expression changes in genes involved in growth signaling, cell cycle, stress response, immunity, metabolism and development. Hep3B cells overexpressing TAp73β had lost hepatocyte lineage biomarkers including ALB, CYP3A4, AFP, HNF4α. In contrast, TAp73β upregulated genes promoting cholangiocyte lineage such as YAP, JAG1 and ZO-1, accompanied with an increase in metastatic ability. Our findings suggest that TAp73β may promote malignant dedifferentiation of HCC cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010471
003      
CZ-PrNML
005      
20210715113152.0
007      
ta
008      
210413s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13040783 $2 doi
035    __
$a (PubMed)33668566
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Iscan, Evin $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
245    10
$a TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation / $c E. Iscan, U. Ekin, G. Yildiz, O. Oz, U. Keles, A. Suner, G. Cakan-Akdogan, G. Ozhan, M. Nekulova, B. Vojtesek, H. Uzuner, G. Karakülah, H. Alotaibi, M. Ozturk
520    9_
$a Hepatocyte dedifferentiation is a major source of hepatocellular carcinoma (HCC), but its mechanisms are unknown. We explored the p73 expression in HCC tumors and studied the effects of transcriptionally active p73β (TAp73β) in HCC cells. Expression profiles of p73 and patient clinical data were collected from the Genomic Data Commons (GDC) data portal and the TSVdb database, respectively. Global gene expression profiles were determined by pan-genomic 54K microarrays. The Gene Set Enrichment Analysis method was used to identify TAp73β-regulated gene sets. The effects of TAp73 isoforms were analyzed in monolayer cell culture, 3D-cell culture and xenograft models in zebrafish using western blot, flow cytometry, fluorescence imaging, real-time polymerase chain reaction (RT-PCR), immunohistochemistry and morphological examination. TAp73 isoforms were significantly upregulated in HCC, and high p73 expression correlated with poor patient survival. The induced expression of TAp73β caused landscape expression changes in genes involved in growth signaling, cell cycle, stress response, immunity, metabolism and development. Hep3B cells overexpressing TAp73β had lost hepatocyte lineage biomarkers including ALB, CYP3A4, AFP, HNF4α. In contrast, TAp73β upregulated genes promoting cholangiocyte lineage such as YAP, JAG1 and ZO-1, accompanied with an increase in metastatic ability. Our findings suggest that TAp73β may promote malignant dedifferentiation of HCC cells.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ekin, Umut $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Yildiz, Gokhan $u Department of Medical Biology, Faculty of Medicine, Karadeniz Technical University, Trabzon 61000, Turkey
700    1_
$a Oz, Ozden $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Keles, Umur $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Suner, Aslı $u Department of Biostatistics and Medical Informatics, Faculty of Medicine, Ege University, Izmir 35000, Turkey
700    1_
$a Cakan-Akdogan, Gulcin $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Department of Medical Biology, Faculty of Medicine, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Ozhan, Gunes $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Nekulova, Marta $u RECAMO, Masaryk Memorial Cancer Institute, 60200 Brno, Czech Republic
700    1_
$a Vojtesek, Borivoj $u RECAMO, Masaryk Memorial Cancer Institute, 60200 Brno, Czech Republic
700    1_
$a Uzuner, Hamdiye $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Karakülah, Gökhan $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Alotaibi, Hani $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey ; Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35000, Turkey
700    1_
$a Ozturk, Mehmet $u Izmir Biomedicine and Genome Center, Izmir 35000, Turkey
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 4 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33668566 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210715113151 $b ABA008
999    __
$a ind $b bmc $g 1649822 $s 1130847
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 4 $e 20210213 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 113S389 $p TUBITAK
GRA    __
$a - $p Turkish Academy of Sciences
GRA    __
$a - $p Izmir Biomedicine and Genome Center
GRA    __
$a MMCI, 00209805 $p MH CZ - DRO
GRA    __
$a 19-06530S $p Grant Agency of the Czech Republic
GRA    __
$a No.CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund-Project ENOCH
GRA    __
$a - $p EMBO Installation Grant
GRA    __
$a - $p TUBITAK
LZP    __
$a Pubmed-20210413
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace